ProShares Ultra NASDAQ Biotechnology
22 hedge funds and large institutions have $19.2M invested in ProShares Ultra NASDAQ Biotechnology in 2014 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
49% less call options, than puts
Call options by funds: $8.88M | Put options by funds: $17.3M
Holders
22
Holding in Top 10
–
Calls
$8.88M
Puts
$17.3M
Top Buyers
| 1 | +$1.98M | |
| 2 | +$1.32M | |
| 3 | +$1.19M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$704K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$632K |
Top Sellers
| 1 | -$2.4M | |
| 2 | -$933K | |
| 3 | -$883K | |
| 4 |
LPL Financial
San Diego,
California
|
-$720K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$615K |